151P Safety and tolerability of pembrolizumab or placebo plus pemetrexed and platinum as first-line therapy in Japanese patients (PTS) with metastatic non-squamous non-small cell lung cancer (NSCLC) enrolled in the phase III KEYNOTE-189 study.

Autor:	Horinouchi, H1 (AUTHOR), Nogami, N2 (AUTHOR), Saka, H3 (AUTHOR), Nishio, M4 (AUTHOR), Tokito, T5 (AUTHOR), Takahashi, T6 (AUTHOR), Kasahara, K7 (AUTHOR), Hattori, Y8 (AUTHOR), Ichihara, E9 (AUTHOR), Adachi, N10 (AUTHOR), Sawada, T10 (AUTHOR), Shimamoto, T10 (AUTHOR), Noguchi, K10 (AUTHOR), Pietanza, M C11 (AUTHOR), Kurata, T12 (AUTHOR)
Zdroj:	Annals of Oncology. 2019 Supplement, Vol. 30, pN.PAG-N.PAG. 1p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu